Clinical Trial Update: Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing Bepreve to Alrex in moderate to severe allergic conjunctivitis; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Alrex (loteprednol etabonate)
• Bepreve (bepotastine besilate)

Snippet

Sponsor: Southern California College of Optometry at Marshall B. Ketchum University | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED | Results posted: 2019-08-06